- Conditions
- Head and Neck Neoplasms, Cancer of the Head and Neck
- Interventions
- Carboplatin, Cetuximab, RAD001
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 16,003
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Severe Hemophilia B
- Interventions
- Factor IX (rFIXFc), rFIX
- Drug
- Lead sponsor
- Bioverativ Therapeutics Inc.
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 6 more
- Conditions
- Advanced Solid Tumor
- Interventions
- M9466, Irinotecan, Folinic acid, Fluorouracil (5-FU), Bevacizumab, Granulocyte colony stimulating factor (G-CSF)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Pennington, New Jersey • Nashville, Tennessee + 1 more
- Conditions
- Chemotherapy-induced Neutropenia
- Interventions
- Plinabulin, Pegfilgrastim, Saline Placebo, D5W Placebo
- Drug · Other
- Lead sponsor
- BeyondSpring Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Stanford, California • Skokie, Illinois • Louisville, Kentucky
- Conditions
- Retinoblastoma
- Interventions
- filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, topotecan hydrochloride, autologous bone marrow transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 15 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2005
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Muscle Hypertrophy, Strength
- Interventions
- CHO, PRO
- Dietary Supplement
- Lead sponsor
- Auburn University
- Other
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Auburn, Alabama
- Conditions
- Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk, Diabetes, Gestational
- Interventions
- Sliding Scale Insulin, Up-Titration of Home Insulin, Continuous Insulin Infusion, Dexcom G6 Professional Continuous Glucose Monitor
- Drug · Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- Up to 50 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Portland, Oregon • Greenville, South Carolina + 1 more
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab Emtansine, Trastuzumab, Pertuzumab, Paclitaxel, Epirubicin, Doxorubicin, Docetaxel, Cyclophosphamide, 5-Fluorouracil
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,846 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 50
- States / cities
- Scottsdale, Arizona • Oakland, California • Roseville, California + 44 more
- Conditions
- Triple Negative Breast Cancer, Pancreatic Carcinoma, Melanoma, Endometrial Carcinoma
- Interventions
- MCS110, PDR001
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • St Louis, Missouri • Germantown, Tennessee + 1 more
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis, Severe Acute Respiratory Distress Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Interventions
- Tocilizumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 5
- States / cities
- Rockville, Maryland • Las Vegas, Nevada • Oklahoma City, Oklahoma + 1 more
- Conditions
- Brain Cancer, Pediatric Cancers
- Interventions
- Bevacizumab, Lapatinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 6
- States / cities
- Stanford, California • Chicago, Illinois • Cincinnati, Ohio + 3 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
- Interventions
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate, Temsirolimus
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 558
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 356 more
- Conditions
- Axial Spondyloarthrithis, Ankylosing Spondylitis
- Interventions
- Certolizumab Pegol, Placebo
- Biological · Other
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 736 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 16
- States / cities
- Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Erlotinib, Platinum-based chemotherapy
- Drug
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 5
- States / cities
- Albuquerque, New Mexico • Santa Fe, New Mexico
- Conditions
- Purpura, Thrombocytopenic, Idiopathic
- Interventions
- Eltrombopag, Cyclosporine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Schwannomas, Malignant Tumors
- Interventions
- 18F-DCFPyL Injection
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pregnant Patients With Obesity
- Interventions
- High-dose oxytocin, Low-dose oxytocin
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab, Mycophenolate Mofetil, Tacrolimus, Intraportal infusion of islet cells
- Biological · Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Parkinson's Disease
- Interventions
- Levodopa (L-dopa)
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Waldenstrom Macroglobulinemia
- Interventions
- Carfilzomib, Rituximab, Dexamethasone
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Sarcoma, Soft Tissue Sarcoma
- Interventions
- Avastin, Doxorubicin
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hepatic Insufficiency
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Tustin, California • Orlando, Florida • New Orleans, Louisiana
- Conditions
- Neoplasms
- Interventions
- Feladilimab, Ipilimumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Carcinoma, Squamous Cell
- Interventions
- JNJ-90301900 (NBTXR3), Cetuximab, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Duarte, California • La Jolla, California + 23 more